Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

istry and RNAi delivery. The Company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties regarding regulatory approvals for future clinical testing of arimoclomol, including CytRx's planned Phase IIb clinical trial, and the scope of the clinical testing that may be required by regulatory authorities for arimoclomol, risks related to any comparison of clinical data to historical controls in the absence of concurrent placebo controls, uncertainties regarding the timing and amount of revenues, if any, that will be realized by CytRx from the commercialization of arimoclomol, the significant time and expense that will be incurred in developing any of the potential commercial applications for arimoclomol and the potential need for additional capital to fund the development of arimoclomol, as well as other risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon informat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:6/18/2013)... 2013 , Safinamide significantly ... patients as add-on to levodopa Safinamide ... symptoms in fluctuating PD patients as add-on to ... S.p.A. ("Newron"), a research and development company focused ... partner Zambon S.p.A., a pharmaceutical company strongly committed ...
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: ... injectable drug delivery systems, today announced the launch of ... new site includes additional products, videos, features, blogs and ... basis. Mr. Alan Shortall , the ... for injectable drug delivery systems, we have created an ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Unilife Launches New Corporate Website 2
(Date:6/19/2013)... (PRWEB) June 19, 2013 GoTunes Inc. ... a free music and fitness app for creating and ... discover new Spotify songs that match your exercise pace, ... exercise, and add songs to your favorite playlists. You ... curated by the GoTunes staff. , Get the free ...
(Date:6/19/2013)... 2013 The reason for the popularity of ... can place a 4x8 flood tray inside the 5’x9’ and ... around. In addition, Gorilla Grow Tents are more like ... tallest, thickest and strongest grow tents on the market, Gorilla ... standards. , Gorilla Grow Tents are made for ...
(Date:6/19/2013)... Santa Ana, CA (PRWEB) June 19, 2013 ... the approval of an Abbreviated New Drug Application (ANDA) ... vial; a generic version of Bristol-Myers Squibb’s drug fomerly ... in response to varied inquiries regarding the anticipated approval ... USP drug product. , Regarding the status of our ...
(Date:6/19/2013)... 19, 2013 Scott Tischler of Tischler Brothers ... swim suit season. , 1.    The very first thing that should ... glass of ice cold water. The body is dehydrated when ... will keep the body hydrated and will also kick start ... to raise the temperature of the water to body temperature ...
(Date:6/19/2013)... 19, 2013 The Report "Data ... VPN, DNS, SSL, DLP, UTM, IAM, SIEM, DR, ... Surveillance, Analytics)]: Global Advancements, Forecasts & Analysis (2013-2018)", ... market into various sub-segments with in-depth analysis and ... restraints for this market with insights into trends, ...
Breaking Medicine News(10 mins):Health News:The GoTunes Iphone App Creates a Streaming Workout Music Community Via Spotify 2Health News:Stealth Grow Tent Brand’s Popularity Rises 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets 2Health News:Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets 3Health News:Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets 4
... ON, June 22 /PRNewswire-FirstCall/ - Bioniche Life Sciences ... biopharmaceutical company, today provided an update on its ... that it was experiencing delays in concluding a ... Complex (MCC), formulated as Urocidin(TM), for the intravesical ...
... , BOSTON, June 22 Bringing the next ... Informatics, a leading eClinical solutions provider and subsidiary ... ), today announced that it has launched its ... and access to data across multiple technologies throughout ...
... SINGAPORE, June 22 /PRNewswire-Asia/ -- 11th of June ... as well as the Optical industry,in Korea. Recognizing the ... performance of the optical market in Korea, the Korean ... between both,organizations. This partnership will add and build on ...
... ... its 52nd center in South Elgin. , ... Oak Brook, IL (Vocus) June 22, 2009 -- AthletiCo, an Illinois-based leader in ... South Elgin center is located at 722 N. McLean Blvd in South Elgin. AthletiCo ...
... With the outbreak of H1N1 influenza in several countries, people ... effectively prevent the disease from spreading. The discussion for a ... topic around the world. In fact, the vaccine market has ... and globally for quite some time now. , , ...
... that Caucasians are much more likely than people in other ... cancer called Ewing,s sarcoma. In addition, among Caucasians with this ... in the August 1, 2009 issue of CANCER , ... indicates that examining the gender and racial differences related to ...
Cached Medicine News:Health News:Bioniche Provides a Corporate Update 2Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 2Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 3Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 4Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 5Health News:GfK Asia Expands into Korea Optics Industry Partnership Network 2Health News:GfK Asia Expands into Korea Optics Industry Partnership Network 3Health News:AthletiCo Opens 52nd Physical Therapy Center in South Elgin 2Health News:AthletiCo Opens 52nd Physical Therapy Center in South Elgin 3Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 2Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 3Health News:Caucasians are at higher risk of developing Ewing's sarcoma than other races 2
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Manual Table For Slit Lamp...
New!...
Medicine Products: